Navamedic ASA (0FDB.L)

36,50 -0,69 (-1,86%) In data: 06:07PM BST. Mercato aperto.

Navamedic ASA

Henrik Ibsensgate 100
Oslo 0255
Norway
47 941 61 078
https://navamedic.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 45

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Ms. Kathrine E. Gamborg Andreassen	Chief Executive Officer	5,51M	N/D	1966
Mr. Lars Hjarrand	Chief Financial Officer	3,14M	N/D	N/D
Tony Brejke	Chief Operating Officer	N/D	N/D	N/D
Ms. Astrid J. Torgersen Bratvedt	Chief Scientific Officer	N/D	N/D	N/D
Mr. Ole Henrik Eriksen	Chief Business Development Officer	N/D	N/D	1960

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in NOK.

Descrizione

Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Norway, Sweden, Denmark, Finland, the Netherlands, and internationally. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic and propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet. In addition, the company provides consumer health products consisting of non-prescription drugs and health care products for pain relief, cough and cold, gastro, obesity, women's health, and others primarily through pharmacies and drugstores; prescription medicines covering obesity, Parkinson's disease, urology, and cardiology; and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was founded in 2002 and is headquartered in Oslo, Norway.

Governance aziendale

L'ISS Governance QualityScore di Navamedic ASA al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.